SUBSCRIBE
SUBSCRIBE
News   FDA

Pfizer Inc.'s Drug for Nerve Pain, Lyrica Gets Expanded Approval In Japan

October 29, 2010 | 
1 min read

Oct 28 (Reuters) - Japanese health regulators approved Pfizer Inc’s (PFE.N) Lyrica to treat a type of nerve pain called peripheral neuropathic pain, Pfizer said on Thursday.

FDA Approvals Asia
Pfizer
MORE ON THIS TOPIC
Roche's tower in Shanghai, China
Approvals
Roche Continues Regulatory Run With Acute Stroke Expansion for Heart Attack Drug
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Signage at Pfizer's world headquarters in New York City
Manufacturing
Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac